Biogen: Reversal Of Collateral Estoppel Ruling Controls New Appeal
WASHINGTON, D.C. — The maker of the multiple sclerosis (MS) drug Tecfidera in a Feb. 22 appellant brief argues that before deciding whether a federal judge in Delaware erred when ruling...To view the full article, register now.
Already a subscriber? Click here to view full article